Michal Hershkovitz

Michal Hershkovitz is an accomplished professional with extensive experience in regulatory affairs and clinical management. Currently serving as Vice President at DarioHealth since February 2019, Michal previously held the role of Vice President at Exalenz Bioscience Ltd. from June 2018 to January 2019. Prior experience includes a significant tenure at Medinol from August 2008 to November 2017 as Vice President of Clinical & Regulatory Affairs, where successful management of five multicenter global clinical studies and regulatory approvals for class 3 and combination products was achieved. At Teva Pharmaceuticals, from June 1996 to November 2008, Michal functioned as Senior Director of Regulatory Affairs, establishing a proficient global team and preparing strategic regulatory plans. Michal graduated with a BSc in Chemical Engineering from the Technion - Israel Institute of Technology.